03-16112. General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

    Name of Committee: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee.

    General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

    Date and Time: The meeting will be held on July 24, 2003, from 8 a.m. to 5 p.m.

    Location: Hilton Washington, DC North/Gaithersburg, Ballroom Salons A, B, and C, 620 Perry Pkwy., Gaithersburg, MD.

    Contact Person: David Krause, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090, ext. 141, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12519. Please call the Information Line or access the “CDRH Advisory Committees” Web page at http://www.fda.gov/​cdrh/​panelmtg.html for up-to-date information on this meeting.

    Agenda: The committee will discuss and make recommendations on the reclassification of a transitional class III device, the absorbable hemostatic agent and dressing device intended for hemostasis during surgical procedures. There will also be a discussion of clinical trial issues for devices designed for percutaneous removal of breast tumors. Background information for each topic, including the agenda and questions for the committee, will be available to the public 1 business day before the meeting on the Internet at http://www.fda.gov/​cdrh/​panelmtg.html.

    Procedure: On July 24, 2003, from 8:30 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 10, 2003. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 8:45 a.m., 11 a.m. and 11:15 a.m., and 1:15 p.m. and 1:45 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 10, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

    Closed Committee Deliberations: On July 24, 2003, from 8 a.m. to 8:30 a.m., the meeting will be closed to permit FDA to present to the committee trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) relating to pending issues and applications.

    Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

    FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, at 301-594-1283, ext. 113, at least 7 days in advance of the meeting.

    Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

    Start Signature

    Dated: June 19, 2003.

    Peter J. Pitts,

    Associate Commissioner for External Relations.

    End Signature End Preamble

    [FR Doc. 03-16112 Filed 6-25-03; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Published:
06/26/2003
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
03-16112
Pages:
38067-38067 (1 pages)
PDF File:
03-16112.pdf